v3.26.3
Segment information
 6 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment information Segment information
The Company manages its operations as a single operating and reportable segment with a focus on developing and commercializing novel oncolytic immunotherapies in order to treat cancer. The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed to analyze financial performance and make operating decisions. The Company’s Chief Operating Decision Maker ("CODM") is the Chief Executive Officer. The CODM reviews consolidated operating results, and uses the Company's loss from operations and consolidated net income (loss), in order to monitor actual results as compared to the budget, and to determine how best to allocate the Company's operating and capital resources, specifically as it relates to the Company's development programs.
The following table presents selected financial information with respect to the Company's single operating segment, including significant segment expenses by program, for the three and six months ended September 30, 2026 and 2025:
Three Months Ended
September 30,		Six Months Ended
September 30,
2026202520262025
Operating expenses:(Amounts in thousands)
Direct research and development expenses by program:
RP1 program costs by study:
IGNYTE$903 $2,562 1,578 6,014 
ARTACUS648 1,616 1,132 3,235 
CERPASS176 1,433 (94)2,640 
IGNYTE-36,818 6,474 14,768 11,335 
Other RP1 study costs39 5,539 1,439 9,963 
RP29,439 5,253 18,266 9,128 
RP3303 580 549 1,437 
Unallocated research and development expenses¹:16,039 34,420 46,006 71,969 
Selling, general and administrative21,916 26,414 40,885 58,994 
Total operating expenses56,281 84,291 124,529 174,715 
Loss from operations(56,281)(84,291)(124,529)(174,715)
Other (expense) income, net(840)$1,191 $(2,358)$4,922 
Net loss(57,121)(83,100)(126,887)(169,793)
¹Includes personnel-related costs and other costs